Home > PJ (current issue) > Onlooker | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 271 No 7256 p28
5 July 2003

This article
Reprint
Photocopy

   

PDF* 75K

Onlooker

Puzzling patents [more]
Art and arsenic [more]
Medicate and meditate [more]
Essential unity [more]


Puzzling patents

Picking a path through the tangle of patent legislation has become a nightmare for producers of new products derived from natural features of the jungle, the desert and the oceans, who are trying their hardest to stop other producers making profits out of the same features.

It is clearly established that the discoverer of a naturally occurring phenomenon such as an element, a chemical or a mineral cannot protect himself by patenting it. Although a genetically modified organism may be patentable in some circumstances, a new plant or mineral discovered in the wild cannot, because to claim patent rights the intervention of human ingenuity has to be proven.

A commentary published in Science for 30 May discusses some of the complications that can render a product patentable. The path is by no means clear, since much may depend upon legal arguments over definitions and terms.

In the United States, prohibition regarding patents for some natural substances has been allowed to lapse if they are merely isolated and purified without substantial modification. This has resulted in patent cover for some minerals, extracts and secretions of micro-organisms, vitamins and viruses, despite the fact that they have not undergone any process of "human ingenuity" worth talking about. Sometimes conversion of a chemical ester into a salt, or the addition of small quantities of an impurity, has earned patent rights.

Fundamentally, there should be a prerequisite of the element of "human ingenuity" in the conversion of a natural product into a utility before patenting is allowed. There is at present no test that will distinguish between a product of nature and the result of human ingenuity.

In chemistry and the physical sciences the character of a natural substance and the product must be substantially different for a patent to be allowable. If there are differences, it must be determined whether they are inherent in the natural product or brought about by the claimant. The fact that a process may be patented does not guarantee that the final product is patentable. Remaining factors are utility and novelty. A profusion of patents on products of nature diverts resource into licence fees and litigation proceedings. Fear of such expenses may deter further research and so loss of public benefit. Would-be patenters should walk cautiously.

Back to Top


Art and arsenic

An interesting observation is made by Andy Meharg of Aberdeen University in Nature for 12 June, regarding William Morris and arsenical poisoning. Morris's father was one of the directors of the mining company Devon Great Consuls, which in its day was the largest producer of arsenic in the world. Morris himself used his income from shares in this company to finance his design company Morris, Marshall, Faulkner & Co, and was also a director of his father's company from 1871 to 1875, when he became an ardent socialist and abandoned capital interests.

Devon Great Consuls was a major supplier of arsenic for the production of green pigments, and in particular copper arsenite, Scheele's green, widely used in wallpapers. When walls became damp, fungi living on the wallpaper paste produced highly toxic trimethylarsine, which on inhalation by a room's occupants often caused chronic illness and death. Letters to one of Morris's dye manufacturers, Thomas Wardle, indicate that the artist was made aware that concern was felt over the possible toxicity of the wallpaper pigments, but dismissed the idea as a scare.

In an investigation of the use of arsenical pigments in Morris wallpaper, a sample of a pattern produced from 1864 was examined by energy dispersive analysis, which revealed that the green colour was indeed a copper arsenical salt. It is ironic that a writer who demonised the industrial practices of his time as dehumanising should have turned a blind eye to his own role in promoting the highly polluting production of arsenicals, apparently even showing indifference to the situation when it was pointed out to him.

Back to Top


Medicate and meditate

In the issue of 17 May of the BMJ appears an editorial on the vexed question of meditation during illness, and whether it can be of any help if added to the many different therapies which we have available to us today. The article asserts that the physiological effects that appear during meditation may indicate a degree of relaxation under strain, but do not prove that meditation has any therapeutic value in its own right. Clinical trials of meditation therapy have had weak designs and have been almost uncontrolled in the manner we expect in clinical trials of clinical remedies.

It is unfortunate that most published research into transcendental meditation, by which we mean an attempt to induce someone's detachment from current problems which loom near and consequent relief from anxiety, is carried out by its own exponents and judged by their standards, not by an unbiased and independent investigator. "Overall", comments Peter H. Canter of Exeter in the editorial, "current evidence for the therapeutic effectiveness of any type of meditation is weak".

A similar conclusion was recorded in the New England Journal of Medicine three years ago when discussing current opinion among people in the United States that religious and spiritual considerations should be an integral part of medical care. Although they may play a part in helping a patient, they should be kept distinct from strictly clinical procedures. Meditation, like prayer, is recognised as offering a powerful means for concentrating the mind in some individuals. If we can help a sick person to think hard about the problems inherent in any process of suffering, bodily or mental, there must be advantage to be achieved.

It has been noted that in individuals suffering incurable and terminal illness in particular, the patient may well develop hope for the future which serves to reduce any suffering which must be endured. Whether the means adopted for mental concentration is an indwelling religious faith or the outcome of a more generalised meditation on existence in general matters very little.

Viewed in this light, there is scope for the spiritual healer to assist the medical expert in guiding a sufferer towards a brighter outlook.

Back to Top


Essential unity

In our universities the arts block and the science block tend to be well separated. But we will never make much sense of life if we do not somehow keep our various faculties on speaking terms with one another
— Mary Midgely: 'Science and poetry', 2001.

Back to Top


  * PDF files on PJ Online require Acrobat Reader 4 or later


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal